Recursion Pharmaceuticals Gross Profit

As of the most recent data (June 2026), RXRX shows a gross profit of $-11M. That compares with $-2.4M in the prior-year period — down 341.3% year over year. That is below the Healthcare sector average of $67B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RXRX's gross profit is now $-11M (was $-2.4M) — a 341.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Recursion Pharmaceuticals is outperforming or lagging.

The Healthcare sector average gross profit is about $67B. Recursion Pharmaceuticals is at $-11M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how RXRX stacks up against individual peers as well.

Tracking RXRX's gross profit over time shows whether Recursion Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-11M That compares with $-2.4M in the prior-year period — down 341.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Recursion Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $-11M) with ownership activity and broader fundamentals.